Johnson & Johnson to acquire Momenta Pharmaceuticals for $6.5B

The real value for Johnson & Johnson is Momenta’s pipeline, led by a potential drug for anemia.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.